Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Provides New Info on COVID Study

Stockhouse Editorial December 17, 2020

Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data

GlobeNewswire December 17, 2020

Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire December 16, 2020

IIROC Trade Resumption - AGN

Canada NewsWire December 15, 2020

Algernon Announces Positive Trending Interim Data for COVID Study

Stockhouse Editorial December 15, 2020

Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study

GlobeNewswire December 15, 2020

IIROC Trading Halt - AGN

Canada NewsWire December 14, 2020

Algernon Pharmaceuticals Enrolls Final Patient in Human Study for COVID-19 Treatment

Stockhouse Editorial November 30, 2020

Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire November 30, 2020

Algernon Pharmaceuticals Announces 154 Patients Enrolled in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

GlobeNewswire November 23, 2020

Australian Clinical Research Grants Algernon $600k Tax Credit

Stockhouse Editorial November 16, 2020

Algernon Pharmaceuticals Announces Receipt of Refundable Tax Credit from Australian Clinical Research

GlobeNewswire November 16, 2020

Algernon Pharmaceuticals Provides Update on its Ifenprodil Phase 2 Clinical Trials Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

GlobeNewswire November 13, 2020

Algernon to Provide Interim Data from COVID-19 Human Study

Stockhouse Editorial November 9, 2020

Algernon Pharmaceuticals Announces Plans to Provide Interim Data from its Ifenprodil Phase 2b/3 COVID-19 Human Study

GlobeNewswire November 9, 2020

Data and Safety Monitoring Board Approve Algernon’s COVID Study

Stockhouse Editorial October 30, 2020

Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

GlobeNewswire October 30, 2020

25% Enrollment in Algernon’s Phase 2 Chronic Cough Study

Stockhouse Editorial October 13, 2020

Algernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

GlobeNewswire October 13, 2020

Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific Advisory Board

GlobeNewswire October 9, 2020